🇺🇸 FDA
Pipeline program

REGN7544

R7544-POTS-2429

Phase 2 small_molecule active

Quick answer

REGN7544 for Postural Orthostatic Tachycardia Syndrome (POTS) is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Postural Orthostatic Tachycardia Syndrome (POTS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials